

Insilico Medicine launches industry's first drug discovery and development Benchmark as a Service

August 1, 2026 | News

To evaluate frontier AI and foundation models on real-world science



Hong Kong headquartered Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced the launch of the Drug Discovery and Development (DDD) Benchmarks as a Service (BaaS).

It is a pioneering standardised evaluation framework anchored in carefully decontaminated real-world data and proprietary validated programs. for measuring how frontier AI and foundation models built on other architectures perform on real-world tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research.

Insilico's BaaS is available to any organisation developing frontier AI for drug discovery or leveraging foundation models in their research. The DDD Benchmark provides an independent, real-world measure of how a model performs.

The DDD Benchmark comprises two complementary evaluation suites:

Drug Discovery Foundations includes more than 300 evaluations built from proprietary out-of-distribution test sets and rigorously decontaminated public data.

Drug Candidate Essentials evaluates a model's ability to navigate an end-to-end drug discovery programme, from hit identification through preclinical candidate (PCC) nomination.

Benchmarking is straightforward: any model served through a standard chat-completions API can be evaluated by contacting Insilico Medicine. Insilico Medicine scores the resulting outputs against expert reference baselines and provides a standardised scorecard comparing performance with leading models.

The DDD Benchmark builds on Insilico's Pharma.AI platform and the MMAI Gym, the company's post-training environment for scientific AI.